Solid Biosciences Inc
Research Solid Biosciences Inc (SLDB) on Bullrun: market cap USD 1.04B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLDB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.04B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 54.80M
- Free cash flow-USD 52.74M
Valuation Snapshot
latest market cap is USD 1.04B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 174.33M | -USD 157.44M | n/a | -1.99 | USD 59.90M | USD 21.16M | USD 180.01M |
| FY2024 | USD 0 | -USD 124.70M | -USD 100.67M | n/a | -3.06 | USD 80.24M | USD 24.18M | USD 137.25M |
| FY2023 | n/a | -USD 96.02M | -USD 95.70M | n/a | -4.83 | USD 74.02M | USD 26.27M | USD 126.48M |
| FY2022 | USD 8.09M | -USD 85.98M | -USD 100.99M | n/a | -10.1 | USD 155.38M | USD 24.99M | USD 211.67M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.04B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 445.38M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 161.87M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 123.89M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 105.06M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 193.10M | n/a | n/a | n/a |
About Solid Biosciences Inc
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Solid Biosciences Inc's market cap?
Solid Biosciences Inc's market capitalization is USD 1.04B.
What does Solid Biosciences Inc do?
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.